MARKET

GKOS

GKOS

Glaukos
NYSE

Real-time Quotes | Nasdaq Last Sale

85.41
+1.68
+2.01%
Opening 15:34 03/05 EST
OPEN
83.85
PREV CLOSE
83.73
HIGH
85.79
LOW
79.68
VOLUME
353.26K
TURNOVER
--
52 WEEK HIGH
99.00
52 WEEK LOW
23.31
MARKET CAP
3.91B
P/E (TTM)
-31.3615
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 2)
Benzinga · 2d ago
The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 1)
Benzinga · 3d ago
Glaukos Announces Participation in Oppenheimer Healthcare Conference
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually pa...
Business Wire · 3d ago
Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana W...
Business Wire · 3d ago
10-K: GLAUKOS CORP
(EDGAR Online via COMTEX) -- ITEM 7.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 4d ago
Global Micro-Invasive Glaucoma Implants Market 2020 Key Players, SWOT Analysis, Key Indicators, Forecast and COVID-19 Impact Analysis 2025
Mar 01, 2021 (CDN Newswire via Comtex) -- The recently uploaded report titled Global Micro-Invasive Glaucoma Implants Market 2020 by Manufacturers, Regions,...
CDN Newswire · 4d ago
DJ Glaukos' CEO Tom Burns on Q4 2020 Results -- Earnings Call Transcript >GKOS
Dow Jones · 5d ago
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
Zacks.com · 02/26 19:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of GKOS. Analyze the recent business situations of Glaukos through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average GKOS stock price target is 87.89 with a high estimate of 111.00 and a low estimate of 48.00.
EPS
Institutional Holdings
Institutions: 334
Institutional Holdings: 60.74M
% Owned: 132.67%
Shares Outstanding: 45.79M
TypeInstitutionsShares
Increased
61
2.68M
New
70
-1.58M
Decreased
64
2.93M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+2.89%
Healthcare Equipment & Supplies
+2.10%
Key Executives
Chairman/Independent Director
William Link
President/Chief Executive Officer/Director
Thomas Burns
Chief Financial Officer/Senior Vice President
Joseph Gilliam
Chief Operating Officer
Chris Calcaterra
Other
L. Jay Katz
Director
Gilbert Kliman
Independent Director
Mark Foley
Independent Director
David Hoffmeister
Independent Director
Marc Stapley
Independent Director
Denice Torres
Independent Director
Aimee Weisner
Independent Director
Leana Wen
No Data
About GKOS
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Webull offers kinds of Glaukos Corp stock information, including NYSE:GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.